Serum Cholinesterase in Patients with Fatty Liver

Nomura, Fumio; Ohnishi, Kunihiko; Koen, Hirofumi; Hiyama, Y; Nakayama, Toshiko; Itoh, Yoshimi; Shirai, Kohji; Saitoh, Yasushi; Okuda, Kunio

doi:10.1097/00004836-198610000-00025

Cited by 33 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…47 However, these data still require wider con¢rmation since, to our knowledge, serum ChE is still rarely evaluated in obese patients. The present results contradict those of Nomura et al 46 and Kutty et al, 47 as no alteration was found in any of the periods evaluated (Table 1) and the activity of ChE was close to the reference range ( Table 2), suggesting that neither excess weight nor the loss of weight in£uenced its value.…”

Section: Discussioncontrasting

confidence: 94%

Steatosis and hepatic markers before and shortly after bariatric surgery

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 94%

Steatosis and hepatic markers before and shortly after bariatric surgery

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Significant increases of the serum AST, ALT, GGT, and ChE activities in groups of patients with non-alcoholic fatty liver disease are well documented (15–22), as well as its correlation with the grade of steatosis and fibrosis assessed by liver ultrasound (17,19,20). In particular, increased serum ChE is considered a useful marker of liver steatosis (21,32), associated with adiposity, insulin resistance, lipid profile (22,33), and fatty liver infiltration degree (34). The serum levels of AST, ALT, GGT, and ChE, and AST/ALT ratio, APRI and FIB-4 indices were analogous and without significant differences between the groups of VPA-treated patients with ceruloplasmin-specific oxidase activities lower or greater than 333 U/L (Tables I and II).…”

Section: Discussionmentioning

confidence: 99%

A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid

Lampón

Tutor

2010

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

BackgroundPatients treated with valproic acid (VPA) present a high incidence of non-alcoholic fatty liver disease (NAFLD) (around 61%). Several recent studies suggest that low copper stores could be associated with NAFLD, and a significant decrease of copper availability in VPA-treated patients has been described.Design and methodsIn 101 adult epileptic patients treated with valproic acid in monotherapy (n = 75) and polytherapy (n = 26) the copper availability was evaluated using the specific oxidase activity of ceruloplasmin (activity per unit mass of enzyme protein) and the copper/ceruloplasmin ratio. Copper deficiency was supposed in the cases in which this biochemical variable was smaller than the lower reference limit (333 U/g).ResultsThe differences between the groups of patients with ceruloplasmin oxidase activity smaller or greater than 333 U/g for the serum levels of aminotransferases, gamma-glutamyltransferase, butyrylcholinesterase, cholesterol, triglycerides, and C-reactive protein, and the APRI and FIB-4 liver fibrosis scores were not statistically significant. Most patients (93%) had low APRI and FIB-4 scores, suggesting absence of significant liver fibrosis.ConclusionsThe results obtained do not confirm the hypothesis of an association between diminished copper availability and NAFLD in patients treated with valproic acid.

show abstract

“…Increased BChE activity has been observed in nonobese as well as obese patients with fatty liver, whereas obese subjects without liver changes showed levels in the upper normal range. In subjects with fatty liver submitted to a low caloric diet, BChE activity decreased in parallel with the improvement of hepatic steatosis .…”

Section: Obesity and Metabolic Syndromementioning

confidence: 94%

Butyrylcholinesterase as a prognostic marker: a review of the literature

Santarpia

Grandone

Contaldo

et al. 2012

J cachexia sarcopenia muscle

230

171

View full text Add to dashboard Cite

BackgroundButyrylcholinesterase (BChE) is an α-glycoprotein synthesized in the liver. Its serum level decreases in many clinical conditions such as acute and chronic liver damage, inflammation, injury and infections, and malnutrition.Methods and resultsThis review collects the main evidence on the emerging role of butyrylcholinesterase as a prognostic marker of liver and nonliver diseases as well as a marker of protein-energy malnutrition and obesity. In fact, serum concentrations and BChE activity seem to accurately reflect the availability of amino acidic substrates and/or derangement in protein synthesis due to hepatocellular damage. In cancer, with or without liver impairment, serum BChE levels serve as an accurate functional and prognostic indicator, useful for monitoring clinical and therapeutic interventions according to patients’ prognosis. In the absence of inflammation, BChE could also serve as an index of the effectiveness of nutritional support.ConclusionsSerum BChE assessment should be included in routine clinical diagnostic procedures to evaluate patient clinical conditions, in particular in cases of inflammation and/or protein-energy malnutrition.

show abstract

Serum Cholinesterase in Patients with Fatty Liver

Cited by 33 publications

References 0 publications

Steatosis and hepatic markers before and shortly after bariatric surgery

Steatosis and hepatic markers before and shortly after bariatric surgery

A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid

Butyrylcholinesterase as a prognostic marker: a review of the literature

Contact Info

Product

Resources

About